2. Academic Validation
  3. SAR studies in the sulfonyl carboxamide class of HBV capsid assembly modulators

SAR studies in the sulfonyl carboxamide class of HBV capsid assembly modulators

  • Bioorg Med Chem Lett. 2019 Aug 15;29(16):2405-2409. doi: 10.1016/j.bmcl.2019.05.029.
Scott D Kuduk 1,  Angela M Lam 2,  Christine Espiritu 2,  Robert Vogel 2,  Vincent Lau 2,  Klaus Klumpp 2,  Osvaldo A Flores 2,  George D Hartman 2
Affiliations

Affiliations

  • 1 Novira Therapeutics, a Janssen Pharmaceuticals Company, 1400 McKean Road, Spring House, PA 19477, United States. Electronic address: skuduk@its.jnj.com.
  • 2 Novira Therapeutics, a Janssen Pharmaceuticals Company, 1400 McKean Road, Spring House, PA 19477, United States.
PMID: 31227344 DOI: 10.1016/j.bmcl.2019.05.029
Abstract

The HBV core protein has multiple essential functions in the HBV life cycle to enable chronic HBV Infection. The core protein oligomerizes to form the viral capsid, and modulation of the HBV capsid assembly process has shown clinical efficacy in early clinical trials. Herein is described the SAR exploration of NVR 3-778, the first clinical compound in the sulfonyl carboxamide class.

Keywords

Capsid modulator; Core protein; HBV; Sulfonamide.

Figures